Update of Drug Pricing System in Japan

Hiroaki MAMIYA
Deputy Director
Economic Affairs Division
Health Policy Bureau
Ministry of Health, Labour and Welfare
1. Drug Price Standard system
Medical treatment fee is classified into medical, dental and dispensing fee.
Specifically, medical fee is calculated by adding the scores given to individual medical actions that were provided, converting 1 point to 10 yen, in principle (so called, “fee-for-service system”).
For example, when a patient is hospitalized for appendicitis, the first visit fee, hospital fee according to the number of days of hospitalization, surgery fee for appendicitis, test fee, drug fee, etc. are added. The insurance medical institution will receive the total amount less the co-payment charged to the patient from the examination and payment organization.
Trends in Medical Expenditure

National medical expenditure as a percentage of national income

National medical expenditure (trillion yen)

The ratio of national medical expenditure to GDP

Change of qualifying age
(70 and over → 75 and over)

Medical expenditure for the elderly (trillion yen)

Note: Figures in parentheses represent medical expenditure for the elderly (75 and over) as a percentage of national medical expenditure.

Revisions to medical service fees

Major system changes

< Year-on-year growth rates >

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>National medical expenditure</td>
<td>6.1%</td>
<td>4.5%</td>
<td>4.5%</td>
<td>-1.8%</td>
<td>3.2%</td>
<td>-0.5%</td>
<td>1.9%</td>
<td>1.8%</td>
<td>3.2%</td>
<td>-0.0%</td>
<td>3.0%</td>
<td>2.0%</td>
<td>3.4%</td>
<td>3.9%</td>
<td>3.1%</td>
<td>1.6%</td>
<td>2.2%</td>
<td>1.8%</td>
</tr>
<tr>
<td>Medical expenditure for the elderly (75 and over)</td>
<td>12.7%</td>
<td>6.6%</td>
<td>9.3%</td>
<td>-5.1%</td>
<td>4.1%</td>
<td>0.6%</td>
<td>-0.7%</td>
<td>-0.7%</td>
<td>0.6%</td>
<td>-3.3%</td>
<td>0.1%</td>
<td>1.2%</td>
<td>5.2%</td>
<td>5.9%</td>
<td>4.5%</td>
<td>3.0%</td>
<td>3.6%</td>
<td>2.3%</td>
</tr>
<tr>
<td>National income</td>
<td>7.2%</td>
<td>8.1%</td>
<td>1.1%</td>
<td>1.7%</td>
<td>-2.2%</td>
<td>-0.8%</td>
<td>1.2%</td>
<td>0.5%</td>
<td>1.1%</td>
<td>1.1%</td>
<td>0.8%</td>
<td>-6.9%</td>
<td>-3.0%</td>
<td>2.4%</td>
<td>-0.9%</td>
<td>0.7%</td>
<td>2.9%</td>
<td>-</td>
</tr>
<tr>
<td>GDP</td>
<td>7.2%</td>
<td>8.6%</td>
<td>1.8%</td>
<td>0.8%</td>
<td>-1.8%</td>
<td>-0.7%</td>
<td>0.8%</td>
<td>0.2%</td>
<td>0.5%</td>
<td>0.7%</td>
<td>0.8%</td>
<td>-4.6%</td>
<td>-3.2%</td>
<td>1.3%</td>
<td>1.3%</td>
<td>0.1%</td>
<td>1.8%</td>
<td>-</td>
</tr>
</tbody>
</table>

Note 1: National income and GDP are from “National economic accounting” published by Cabinet Office. Being used to compare the medical expenditure among OECD countries, total healthcare expenditure is a type of medical expenditure which covers wider areas such as preventative services and so on. The ratio of average medical expenditure of OECD countries to GDP was 9.3% in 2012.

Note 2: The national medical expenditure for FY2013 (and medical expenditure for the latter-stage elderly people (75 and over)) is an estimate. The estimate for FY2013 is made by multiplying the FY2012 national medical expenditure by the growth rate of the rough estimate of FY2013 medical expenditure (stated above in italics).
National Health Insurance Drug Price Standard

Items and prices of drugs usable in insurance-covered healthcare, specified by the Minister of Health, Labour and Welfare (common for all medical insurance systems, including health insurance, National Health Insurance (NHI), and various mutual aid systems)

• Item list
  – A doctor or pharmacist operating under the health insurance program, in principle, must not use drugs other than “Drugs the Minister of Health, Labour and Welfare specifies”.
  – Items listed in the NHI Drug Price Standard are stipulated as “Drugs the Minister of Health, Labour and Welfare specifies”.
  = **NHI Drug Price Standard specifies drugs usable in insurance-covered healthcare, and functions as an item list.**

• Price table
  – When an authorized medical institution or pharmacy operating under the health insurance program makes insurance claims, the drug charge shall be calculated based on the price specified in the NHI Drug Price Standard.
  = **NHI Drug Price Standard specifies the claimable amount of drugs used in insurance-covered healthcare, and functions as a price table.**
Revision of price of listed drugs

The actual purchase prices paid by medical institutions and pharmacies (prevailing market price) are surveyed (drug price survey) and the prices specified in the drug price standard are revised periodically based on the results of the survey.
New drugs price determination process

1. Pharmaceutical approval

   NHI price listing application

2. 1st Drug Pricing Organization

   Notification of pricing plan

   - No complaint
   - Complaint

   Submission of appeal document

3. 2nd Drug Pricing Organization

   Notification of investigation result

   Report and approval of pricing plan at general meeting of CSIMC*

   NHI price listing (4 times per year)

* Central Social Insurance Medical Council

Opinion of NHI price listing applicant who desires to express opinions

In principle, within 60 days, within 90 days at latest
New drug price determination method

New drug

Comparable drug exists

Price determination by comparable drugs (I)

Corrective premium

No comparable drug exists

Price determination by comparable drugs (II)

New drug lacking in novelty

Cost accounting system

Adjustment to average overseas price

Adjustment among standards
Price determination by comparable drugs

• When there are comparable drugs with similar efficacy, the daily drug price of the new drug is matched to the daily drug price of existing comparable drugs from the viewpoint of ensuring fair competition in the market. [Price determination by comparable drugs (I)]
  
  – A comparable drug shall be, in principle, a new drug within 10 years after NHI price listing and the drug price of generic drugs is not listed.

  \[
  \begin{align*}
  \text{1 tablet} &= ¥50 \\
  \text{3 tablets a day} &= ¥150 \\
  \text{1 tablet} &= ¥X \\
  \text{2 tablets a day} &= ¥2X \\
  \end{align*}
  \]

  \[
  ¥50 \times 3 = ¥X \times 2 \\
  X = 75 \text{ yen}
  \]

• For the relevant new drug, when higher efficacy is identifiable compared to comparable drugs, a corrective premium is applied to the above amount. [Innovativeness premium, usefulness premium, marketability premium, child premium, and sakigake review designation scheme premium]

<table>
<thead>
<tr>
<th>Premium</th>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Innovativeness premium</td>
<td>70-120%</td>
<td>New action mechanism, high efficacy/safety, improvement of disease treatment method</td>
</tr>
<tr>
<td>Usefulness premium</td>
<td>5-60%</td>
<td>High efficacy/safety, improvement of disease treatment method</td>
</tr>
<tr>
<td>Marketability premium</td>
<td>5%, 10-20%</td>
<td>Orphan drug, etc.</td>
</tr>
<tr>
<td>Child premium</td>
<td>5-20%</td>
<td>Dosage and usage expressly includes those pertaining to children, etc.</td>
</tr>
<tr>
<td>sakigake review designation scheme premium</td>
<td>10-20%</td>
<td>Pharmaceutical approval was obtained in Japan ahead of other countries, etc.</td>
</tr>
</tbody>
</table>
Cost accounting system

Add up material cost, manufacturing expenses, etc., if there is no comparable drug

Calculated drug price

- Manufacturing (importing) cost
  - Material cost
  - Personnel expenses
  - Manufacturing expenses
- Sales cost, research cost, etc.
- Operating profit
- Distribution cost
- Consumption tax

Operating profit varies drastically in the range from $-50\%$ to $+100\%$, depending on the level of novelty, efficacy, or safety compared to the existing therapy.

In principle, in case of exceeding the average coefficient for the pharmaceutical industry, calculation is performed using a coefficient.
Adjustment to average overseas price

• For either price determination by comparable drugs (I) or cost accounting system, an adjustment is made if the deviation from the overseas price is large. [Adjustment to average overseas price]

1. Average overseas price (AOP): Average of prices in the US, UK, Germany and France
   (Make adjustment if there is a large discrepancy among overseas prices)

2. Adjustment requirement:
   (1) When above 125% of AOP → Downward adjustment
   (2) When below 75% of AOP → Upward adjustment

   (1) When above 125% \[ \left( \frac{1}{3} \times \frac{\text{Calculated value}}{\text{AOP}} + \frac{5}{6} \right) \times \text{AOP} \]

   (2) When below 75% \[ \left( \frac{1}{3} \times \frac{\text{Calculated value}}{\text{AOP}} + \frac{1}{2} \right) \times \text{AOP} \]

   The upper limit is 200% of the calculated value.

To solve the problem about unapproved and off-label drugs, the items whose development were requested to the private or public sectors, and satisfy all the requirements below, should be excluded from the adjustment.

① The latest date a drug was approved in any of the 4 countries is more than 10 years before the approval date in Japan.

② AOP is less than one third of the calculated value.

Exception: The development costs the manufactures and retailers shouldered are not considered to exceed certain level.
The drug price of the follow-on biologics (biosimilars)

• Case of follow-on products of biotechnology
  : **0.7 multiplication** of the drug price of the original product
    ※ If the medicine is more than 10 items, 0.6 multiplied
    ※ Depending on the degree of clinical trial, up to 10% addition is allowed

• Case of chemically synthesized products
  : **0.5 multiplication** of the drug price of the original product
    ※ If the medicine is more than 10 items, 0.4 multiplied
2. The reform of drug price system in FY2018
Response to a market expansion after drug price listing

- In order to promptly respond to a market expansion beyond a certain extent associated with an additional indication, etc., utilize the new drug listing opportunity (four times a year) to review the drug price.

Drug price survey and drug price revision in the in-between year

- In addition to a drug price revision every two years, also conduct a drug price survey in the in-between year for all products, and based on the survey results, conduct a drug price revision for products with large price discrepancies.

Evaluations of innovation (Review of the premium for new drug development and elimination of off-label drug use and introduction of cost-effectiveness evaluations)

- In order to promote the discovery of innovative new drugs, fundamentally review, on a zero basis, the premium for new drug development and elimination of off-label drug use.
- Along with this, introduce full-scale cost-effectiveness evaluations, including a price increases for drugs with high cost-effectiveness. (Also consider the modality of implementation, including organization and system.)

Future efforts in line with reform

- Thorough implementation of accuracy and transparency of the drug price calculation method
- Improvement of the foreign price adjustment method
- Expeditious understanding of stakeholders’ actual business situation and necessary action
- Prompt provision of new health technologies
- Transformation from a model depending on long-listed products to an industrial structure with stronger drug discovery capabilities
- Expansion of strategies/measures to support the R&D of innovative biopharmaceuticals and biosimilars
- Promotion of support for venture companies and market competition of generic manufacturers
- Improvement of distribution efficiency, promotion of distribution improvements, and appropriate responses to the profit structure associated with the market environment
- Promotion of unit price-based by-product contracts and promotion of early price settlements
## Discussions regarding the Fundamental Reform of the Drug Pricing System

Based on the "Basic Policy for Fundamental Reform of the Drug Pricing System" (December 20, 2016), the Special Committee on Drug Prices initiated specific discussions in January 2017 and held 16 meetings throughout the year until December. Meetings to hear the opinions of the related industries were held three times.

<table>
<thead>
<tr>
<th>Date</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jan. 11</td>
<td>Responses to market expansions associated with additional indications, etc.</td>
</tr>
<tr>
<td>Jan. 25</td>
<td>Modality of foreign price adjustment</td>
</tr>
<tr>
<td>Feb. 8</td>
<td>Drug price surveys</td>
</tr>
<tr>
<td>Feb. 22</td>
<td>Accuracy and transparency of the drug price calculation method (comparator price method)</td>
</tr>
<tr>
<td>Mar. 15</td>
<td>Drug price survey and drug price revision in the in-between year</td>
</tr>
<tr>
<td>Mar. 29</td>
<td>Drug price survey</td>
</tr>
<tr>
<td>Apr. 12</td>
<td>Accuracy and transparency of the drug price calculation method (cost calculation method)</td>
</tr>
<tr>
<td>Apr. 26</td>
<td>Modality of the drug prices of generics</td>
</tr>
<tr>
<td>May 17</td>
<td>Opinion-hearing from the related associations</td>
</tr>
<tr>
<td>May 31</td>
<td>Modality of the drug prices of long-listed drugs</td>
</tr>
<tr>
<td>Jun. 14</td>
<td>Modality of the premium for new drug development and elimination of off-label drug use</td>
</tr>
<tr>
<td>Jun. 28</td>
<td>Evaluations of innovation</td>
</tr>
<tr>
<td>Jul. 26</td>
<td>Summary of discussions up to now (1)</td>
</tr>
<tr>
<td>Aug. 9</td>
<td>Summary of discussions up to now (2)</td>
</tr>
<tr>
<td>Sept. 13</td>
<td>Opinion-hearing from the related associations</td>
</tr>
<tr>
<td>Oct. 27</td>
<td>Other matters</td>
</tr>
<tr>
<td>Nov. 22</td>
<td>Fundamental reform of the drug pricing system (Draft)</td>
</tr>
<tr>
<td>Nov. 29</td>
<td>Opinion-hearing from the related associations</td>
</tr>
<tr>
<td>Dec. 13</td>
<td>Fundamental reform of the drug pricing system (Draft) (Part 2)</td>
</tr>
</tbody>
</table>

December 20: Summarized the Outline for the Fundamental Reform of the Drug Pricing System
Based on the "Basic Policy for Fundamental Reform of the Drug Pricing System" (December 20, 2016), achieve both "Sustainability of the universal healthcare system" and "Promotion of innovation" to realize "Reduction of public financial burden" and "Improvement in the quality of medical care."

### New drugs

**Fundamental review of the premium for new drug development and elimination of off-label drug use**
- **Target products:** To be narrowed down based on the **innovativeness and usefulness**
- **Corporate index:** **Premium in accordance with the level of achievement of the corporate index** (development of innovative new drugs, etc.)

**Prompt response to the market expansion due to additional indications, etc.**
- **Target:** 35 billion yen or higher*
- **Frequency:** 4 times a year (at the time of new drug listings)
  *A reduction of the drug prices according to the re-pricing rule following market expansion

### Review of foreign price adjustments

- **US reference price list**
  - Manufacturer's suggested retail price
  - *Price list in the publish health insurance system*

### Introduction of cost-effectiveness evaluations

- **Trial introduction**
  - Price adjustments will be **conducted** for 13 target products in **April 2018**.
  - **Full-fledged introduction**
  - Technical problems will be summarized and a conclusion will be reached by the end of FY2018.

### Long-listed drugs and generics

**Review of the prices of long-listed drugs**
- **Target:** Long-listed drugs for which 10 years have passed since a generic was launched
- **Review method:** Step-by-step reduction **based on the generic price**

**Consolidation of the generic price**
- **Target:** Generics for which 12 years have passed since they were launched
- **No. of price ranges:** In principle, **1 price range**

---

**Annual drug price survey and annual drug price revision**

- **Scope**: In consideration of the status of the price revision of all products, the government will take the initiative to improve drug distribution and decide on the scope by the end of FY2020.
Future Considerations

Supplementary comments attached to the report concerning the FY2018 medical fee revision (excerpt)

(Fundamental reform of the drug pricing system)

16 Based on the "Outline for the Fundamental Reform of the Drug Pricing System," continue discussing the necessary actions and measures upon verifying the impact of the fundamental reform of the drug pricing system on the stakeholders.
In addition, continue to discuss how to handle basic drugs.

Outline for the Fundamental Reform of the Drug Pricing System Appendix (Approved at the Chuikyo on December 20, 2017) (excerpt)

II. Appropriate evaluations of innovation
1. Fundamental review of the premium for new drug development and elimination of off-label drug use
   2) Corporate requirements and corporate index
      ○ Since the corporate index is to be introduced for the first time on this occasion, in the FY2018 revision, the disparity among companies due to the scope of Classifications I and III and differences in the premium will be limited, and after the FY2018 revision, pharmaceutical companies' efforts and the results of innovative drug development and drug lag elimination will continued to be examined in terms of whether they are appropriate as evaluation criteria while taking into consideration the actual situation surrounding new drug development, etc. in order to discuss the review of and reflection onto the next or later revision.

VI. Future considerations
   ○ For the next revision, examine the evaluations of innovation in terms of whether or not it is necessary to evaluate the innovativeness and usefulness due to additional indications, etc.
   ○ For the next revision, examine the ideal time period until the step-by-step price reduction of long-listed drugs based on (1) the replacement rate to generics, (2) status of generic launches, and (3) responses to stable supply, among other things, after the price reductions of long-listed drugs on this occasion.
   ○ Upon examining the impact of the fundamental reform of the drug pricing system this time, such as review of the premium for new drug development and elimination of off-label drug use and review of the drug price of long-listed drugs, on the development, manufacture, distribution of drugs, when deemed necessary, consider the necessary measures for the next revision.
We established “Special Committee on Cost-Effectiveness Assessment” as a branch of Central Social Insurance Medical Council, out of concern for fiscal impact of growing expensive healthcare technologies. In the FY2016 drug pricing system reform, the cost-effectiveness assessment shall be introduced on a trial basis to evaluate medicine and medical instruments.

**<Discussion at Central Social Insurance Medical Council (CSIMC)>**

2012.5  Establishment of “Special Committee on Cost-Effectiveness Assessment”
  Discuss the relevant drugs, analytical method, and the use of the assessments etc, referring to overseas cases, on about once a month basis

2014.4～2015.11  Examine specific drugs and report the problems to the general meeting. Discuss each issue.

2015.12  Summarize how the cost-effectiveness assessment should be implemented on a trial basis.

2016.4  Trial implementation of the cost-effectiveness assessment

**<The flowchart of the trial implementation of the cost-effectiveness assessment (Outline)>**

The marketers of newly-listed drugs also need to submit data for future discussion though the data would not be used to adjust the price.